Side of LogoAETC National Resource Center HomeSide of LogoTop of BannerSpacerSpacer
AETC Only
Side of Banner
AETC Services and ContactsAETC Education and Training ResourcesSearchAETC National Resource Center Home
Spacer
Spacer
transparent gif
spacespaceClinical Manual > Complaints > Anemia
space
 CONTENTS
1Testing/ Assessment
2Health Maintenance
3ARV Therapy
4ARV Complications
5Complaints
6Diseases
7Pain and Palliative
8Neuropsychiatric
9Populations
10Resources
  
space

Clinical Manual for Management of the HIV-Infected Adult
2006 Edition

Section 5: Complaint-Specific Workups

Anemia

Chapter Contents
Background
Subjective
Objective
Assessment
Plan
Patient Education
References
Figure 1. Diagnostic Evaluation for Anemia
space

Background

Anemia is usually characterized by a hemoglobin level of <14 g/dL in men and <12 g/dL in women. In people with HIV infection, anemia has been linked to poor quality of life and decreased survival, and correction of anemia can improve these parameters.

Anemia has many potential causes and, in HIV-infected individuals, several of these may occur concomitantly. Common causes include:

Anemia of chronic disease, due to HIV infection itself, is very common in patients with low CD4 counts (<200 cells/µL) and high HIV viral loads, as well as in those with low body mass index, and in women, African Americans, and older people (aged >50 years).

Medication-induced anemia, particularly from zidovudine (ZDV) and trimethoprim-sulfamethoxazole (TMP-SMX), is also common and may occur quickly after initiation of these medications. The risk of anemia with a ZDV-containing regimen is of particular concern in resource-limited settings where access to alternative antiretroviral (ARV) medications may be limited and the likelihood of advanced disease when starting ZDV is substantial. Careful monitoring of hemoglobin at 2-4 weeks after initiation of ZDV and regularly thereafter, and continued access to affordable alternatives, are crucial to the success of antiretroviral therapy (ART) in these settings.

S: Subjective

Patients who have gradual declines in hemoglobin may be able to compensate and remain asymptomatic even at very low hemoglobin levels. Others may complain of weakness, fatigue, shortness of breath, pallor, dizziness, syncope, nausea, anorexia, headache, palpitations, chest pain, sleep disturbance, anxiety, malaise, or confusion.

Conduct a careful history, asking about symptoms listed above, as well as the following:

O: Objective

Measure vital signs, with special attention to heart rate and blood pressure. Perform orthostatic measurements. Compare current weight with previous values. Perform a careful physical examination, including the following:

A: Assessment

Remember that more than one cause of anemia may be present. A partial differential diagnosis includes:

P: Plan

Diagnostic Evaluation

Recheck the hematocrit and hemoglobin to confirm anemia, and perform a complete blood count with differential to determine whether other cytopenias are present.

Perform laboratory work and other diagnostic studies as suggested by the history, physical examination, and differential diagnosis. Consider the following as initial tests to determine the cause of anemia:

See Figure 1 for a possible diagnostic approach.

Check the testosterone level in individuals (both men and women) with anemia of uncertain cause, particularly if they have other signs or symptoms of hypogonadism. Perform further testing if indicated by the clinical presentation and results of the initial workup (eg, evaluation for parvovirus B19 or other infection, vitamin B12 deficiency, G6PD deficiency, malignancy, or gastrointestinal blood loss).

Consider bone marrow biopsy if the diagnosis is unclear, if the anemia is chronic or severe, if the initial evaluation does not determine the cause, or if the anemia is accompanied by pancytopenia. Bone marrow biopsy may also be performed to confirm a diagnosis.

Review the patient's medication list for drugs that may cause anemia. Some common medications that may cause anemia are the following:

Refer the patient to hematology or oncology specialists as appropriate.

Treatment

The appropriate treatment depends on the cause and severity of the anemia. Refer to pertinent chapters in Section 6: Disease-Specific Treatment or primary care management guidelines as appropriate.

  • Patients with severe anemia may require transfusion (unless hemolysis is suspected) with or without hospitalization for evaluation and treatment.
  • Consider treating anemia of chronic disease with ART, if it is otherwise indicated, while avoiding medications associated with bone marrow toxicity. Mild anemia often resolves without intervention after the start of ART as the immune system is reconstituted.
  • If drug-induced anemia is suspected, discontinue the offending medication, if possible. For example, for patients taking ZDV in whom other causes of anemia have been excluded, consider substituting another nucleoside/nucleotide analogue in place of ZDV. If it is not possible to alter therapy, consider using erythropoietin (EPO) or red blood cell transfusion to increase the hematocrit.
  • EPO may be used to stimulate red blood cell production. A typical dosage of recombinant human EPO is 40,000 units weekly by subcutaneous injection. Note that EPO replacement is ineffective if the erythropoietin level is >500 international units per liter (check serum EPO levels before treatment) or if iron levels are low. For patients in whom EPO is started, monitor the hemoglobin and hematocrit regularly (eg, every week until stabilized, then every 4 weeks) and adjust the dosage as required.
  • Treat hypogonadal patients with testosterone.
  • Treat iron deficiency with ferrous sulfate 325 mg orally 3 times daily.
  • Treat nutritional deficiencies as indicated. For folate deficiency, give folic acid 1-5 mg daily for 1-4 months; for vitamin B12 deficiency: administer cobalamin 1 g intramuscularly once daily for 7 days, then once weekly for 4 weeks, then once monthly, or 1-2 g orally once daily.

Patient Education

References

space
space
  space

Copyright 2006, the AIDS Education & Training Centers National Resource Center, unless otherwise noted. All rights reserved. Email webmaster@aidsetc.org with questions, comments, or problems. See disclaimer for usage guidelines.